J. Reiffers , S. Castaigne , H. Tilly , E. Lepage , G. Leverger , P. Henon , L. Douay
{"title":"Hematopoietic reconstitution after autologous blood stem cell transplantation: A report of 46 cases","authors":"J. Reiffers , S. Castaigne , H. Tilly , E. Lepage , G. Leverger , P. Henon , L. Douay","doi":"10.1016/S0278-6222(87)80044-X","DOIUrl":null,"url":null,"abstract":"<div><p>Hematopoietic reconstitution using autologous blood stem cells after high-dose chemoradiotherapy has been achieved successfully in patients with acute leukemias,<sup>1–4</sup> non-Hodgkin's lymphomas,<sup>5–6</sup> or solid tumors.<sup>7</sup> Some patients, however, had incomplete hematopoietic engraftment, which may be due to insufficient numbers of progenitors infused or to the recurrence of leukemic cells. <sup>1,8,9</sup> Thus, the question arises: Is there a safe minimum number of blood progenitors that will produce complete hematopoietic reconstitution following supralethal therapy? To answer this question, we reviewed the data from 46 patients who have undergone autologus blood stem cell transplantation (ABSCT) in six different centers in France.</p></div>","PeriodicalId":101030,"journal":{"name":"Plasma Therapy and Transfusion Technology","volume":"8 4","pages":"Pages 360-362"},"PeriodicalIF":0.0000,"publicationDate":"1987-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/S0278-6222(87)80044-X","citationCount":"48","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Plasma Therapy and Transfusion Technology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S027862228780044X","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 48
Abstract
Hematopoietic reconstitution using autologous blood stem cells after high-dose chemoradiotherapy has been achieved successfully in patients with acute leukemias,1–4 non-Hodgkin's lymphomas,5–6 or solid tumors.7 Some patients, however, had incomplete hematopoietic engraftment, which may be due to insufficient numbers of progenitors infused or to the recurrence of leukemic cells. 1,8,9 Thus, the question arises: Is there a safe minimum number of blood progenitors that will produce complete hematopoietic reconstitution following supralethal therapy? To answer this question, we reviewed the data from 46 patients who have undergone autologus blood stem cell transplantation (ABSCT) in six different centers in France.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
